News

Cerapedics Announces Expansion of Colorado Headquarters

Monday, July 08, 2019

WESTMINSTER, Colo., July 8, 2019 /PRNewswire/ -- Cerapedics, a private ortho-biologics company, today announced the expansion of the company's headquarters located in the Denver metropolitan area. Over the past 18 months, Cerapedics has grown from 16 to 44 employees in Colorado and is increasing its facility from 14,000 to 24,000 square feet to accommodate further expansion through the end of 2019. In addition, Cerapedics is expanding its global workforce from 32 to 73 employees worldwide.

"We are excited to grow our Colorado footprint and bring more jobs and career opportunities to the Denver area," said Glen Kashuba, Chief Executive Officer of Cerapedics. "This expansion allows us to further control our value chain by relocating our distribution activities to our corporate headquarters. We now have the potential to double our headcount across key administrative, operational and sales support departments to meet the growing demand for i-FACTOR™ Peptide Enhanced Bone Graft and drive the business for years to come."

Cerapedics commercialized i‑FACTOR beginning in 2016 and has since increased its market space with continued growth of greater than 50% expected in 2019. i-FACTOR is a drug-device combination that accelerates new bone formation in patients with degenerative disc disease. It is in a new category of bone graft technology and is one of only two drug-device combination products approved by the U.S. Food & Drug Administration (FDA).

To further grow its product portfolio and support the company's commitment to enhancing the science of bone repair, Cerapedics is currently enrolling patients in an investigational device exemption (IDE) clinical trial evaluating the safety and efficacy of the next-generation P-15L Peptide Enhanced Bone Graft in transforaminal lumbar interbody fusion (TLIF) surgery.

"We are excited about our future product offering and further advancement of our growing bone graft franchise," said Edward Sawyer, General Manager and Head of Colorado Operations for Cerapedics. "Expanding our facility enables us to double our Colorado staff to best service our customers and our product. We've benefited greatly from our Coloradolocation and are pleased to continue to expand our team of talented professionals. We have found a strong pool of talent upon which to utilize in the Denver Metro Area."

About Cerapedics

Cerapedics is an ortho-biologics company focused on developing and commercializing its proprietary synthetic small peptide (P-15) technology platform. i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. This novel mechanism of action is designed to support safer and more predictable bone formation compared to commercially available bone growth factors. More information can be found at www.cerapedics.com.

CAUTION: P-15L Bone Graft is an Investigational Product limited by Federal (USA) Law to Investigational Use.

Media contact:
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

 
Continue Reading

New State-of-the-Art Facility Increases Agilent's Capacity to Produce Nucleic Acid-Based Therapeutics

Tuesday, June 18, 2019

New facility in Frederick, Colorado, to produce high-quality molecules with the potential to treat cancer and other diseases 
Continue Reading

Pfizer to buy Colorado's Array BioPharma in deal worth $11.4 billion

Monday, June 17, 2019

Pharmaceutical giant Pfizer Inc. is delving deeper into cancer research with a roughly $11.4 billion deal for Array BioPharma Inc., a Colorado drug developer that has seen its shares soar since announcing positive clinical trial results earlier this spring.

Pfizer said Monday it will pay $48 per share in cash for Boulder-based Array, whose product portfolio includes a treatment combination used for advanced skin cancer that is being tested in other cancers as well.

Array said last month that its combination of the drugs Braftovi and Mektovi along with another treatment led to a significant improvement in overall survival in late-stage testing for some patients with colorectal cancer.

The company plans to submit results from that study to U.S. regulators for approval later this year.

Array's share price has jumped 41% since late May and more than doubled so far this year. Pfizer's offer of $48 per share represents a premium of 62% to the stock's closing price of $29.59 on Friday.

Shares of Array surged 60% before Monday's opening bell.

New York-based Pfizer, which makes the breast cancer drug Ibrance and the blood thinner Eliquis, said the boards of both companies have approved the deal.

It will finance the deal with debt and cash, and it expects the transaction to add to earnings per share starting in 2022.

Pfizer, the biggest U.S. drugmaker by revenue, has had several drug approvals in the U.S. or elsewhere so far this year. But it also saw a heavily touted pain drug flop in late-stage clinical testing, placing the drug's future in doubt.

Pfizer shares edged down 5 cents to $42.70 in premarket trading.

 
Continue Reading

CutisPharma Announces Acquisition of Silvergate Pharmaceuticals, Name Change to Azurity Pharmaceuticals

Thursday, June 13, 2019

WOBURN, Mass. (Jun. 12, 2019) – CutisPharma, Inc. announced today its acquisition of Silvergate Pharmaceuticals, Inc. and the unveiling of its new corporate brand for the unified company: Azurity Pharmaceuticals.
 

Colorado BioScience Association Celebrates State’s Collaborative Nature

Monday, June 03, 2019

New Magazine Offers In-Depth Financing Data and Insights on Medical Device and Drug Approvals 
Continue Reading

Seven Researchers Named Boettcher Investigators

Tuesday, May 28, 2019

Newest Class Marks 10th Group Selected Under Webb-Waring Program 
Continue Reading

ArcherDX Announces Close of $60M Financing to Advance Companion Diagnostic and Minimal Residual Disease Monitoring Product Portfolio

Wednesday, May 15, 2019

BOULDER, Colo., May, 15, 2019 /PRNEWSWIRE/-- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, today announced the closing of an up to $60 million Series B financing round led by Perceptive Advisors. The investor syndicate also includes existing investors PBM Capital, Boulder Ventures, Longwood Fund and Peierls Foundation.  

Prima-Temp Announces New Leadership, Investment, and CE Mark Certification

Wednesday, May 08, 2019

BOULDER, Colo., May 3, 2019 /PRNewswire/ -- Boulder, Colorado based Prima-Temp, Inc. a developer and manufacturer of AI-assisted fertility management products, announced today that in March, it raised $5M in new funding from the Hungarian pharmaceutical company Gedeon Richter, and in April achieved CE mark certification for its Priya Fertility Sensor product. 

AdvaMed President and CEO Releases Statement On the House Bill To Repeal the Medical Device Tax

Thursday, April 11, 2019

WASHINGTON, D.C. – Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed), issued the following statement on introduction of bipartisan legislation (H.R. 2207) in the U.S. House of Representatives to permanently repeal the medical device excise tax:

“America’s medical technology industry is facing a $20 billion tax increase at year-end, when the current medical device tax suspension expires. Urgent action is essential to protect future medtech innovations that benefit patients and to avoid putting good-paying U.S. jobs at risk.

“House introduction today of the ‘Protect Medical Innovation Act of 2019’ in the 116th Congress brings us one step closer to ensuring this innovation-stifling burden on the medtech industry never returns, supporting continued American leadership of this vital industry.

“We thank the bill’s lead sponsors, Reps. Ron Kind (D-Wis.), Jackie Walorski (R-Ind.), Scott Peters (D-Calif.), and Richard Hudson (R-N.C.) for their leadership on this issue. This bill – and the strong bipartisan support they have gathered – reflect the high priority this Congress places on patients, jobs, and future investment.

“While past suspensions of the medical device tax have enabled manufacturers to invest in R&D, infrastructure and new hiring – which in turn benefits patients and the U.S. economy – these benefits are at risk. Now that bipartisan legislation to permanently repeal the device tax has been introduced in both the House and Senate, AdvaMed will urge Congress and the administration to act as expeditiously as possible to get rid of the tax once and for all this year.”

 
Continue Reading

Inscripta Completes $20M Expansion of Series C Financing, Increasing Total Round to $105.5M

Monday, April 08, 2019

Inscripta, a leading gene editing technology company, today announced that it has increased its previously announced Series C financing with an additional $20 million from existing investors. The new funding adds to the $85.5 million financing Inscripta announced in 2018, bringing the total raised for the round to $105.5 million.